Venetoclax and acute myeloid leukaemia: an expanding new frontier

7 de June, 2022 by Susana Ferreira0
Leukemia.png

Venetoclax and acute myeloid leukaemia: an expanding new frontier

Venetoclax is an inhibitor of the anti-apoptotic B-cell lymphoma-2 (BCL-2) protein that has revolutionised the management of acute myeloid leukaemia in the past 5 years. Venetoclax in combination with azacitidine has become the new standard of care for the majority of patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy due to age, fitness, or comorbidities. 1 Venetoclax has improved outcomes for this patient population and represents a valuable new treatment option in this setting. There is now interest in studying venetoclax combined with other acute myeloid leukaemia treatment regimens, including intensive chemotherapy.

Kieran D Sahasrabudhe , Alice S Mims.

© 2022 Elsevier Ltd. All rights reserved.

 

Leukemia


Leave a Reply

Your email address will not be published. Required fields are marked *



New Breathe

WE CARE, WE CAN





New Breathe

WE CARE, WE CAN




0-800-777-2331


24/7 EMERGENCY NUMBER

Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.




2021 © New Breathe. Powered with by Goweb Agency.



2021 © New Breath. Powered with by Goweb Agency.